As­traZeneca en­cour­ages NHL fans to get 'body checked' for can­cer

Last year
Pharma
Marketing

FDA fi­nal­izes rule on us­ing mas­ter files in bi­o­log­ics ap­pli­ca­tions

Last year
Pharma
FDA+

US and EU reg­u­la­tors be­gin of­fer­ing par­al­lel sci­en­tif­ic ad­vice to gener­ic drug­mak­ers

Last year
FDA+

Af­ter 'mis­lead­ing' in­for­ma­tion de­lays FDA in­spec­tion, Chi­nese API man­u­fac­tur­er hit with an OAI

Last year
FDA+
Manufacturing

Ex­clu­sive: In­clud­ed Health makes lay­offs as CEO tar­gets ‘nar­row­er’ lead­er­ship, staff and spend­ing

Last year
Startups
Health Tech

Catal­ent, which is be­ing ac­quired by No­vo, re­ports 10% drop in sec­ond-quar­ter rev­enue

Last year
Manufacturing

Vi­core sells rights to IPF drug in Japan; Roche to lay off 340 work­ers; Sen­so­ri­on’s €50M of­fer­ing

Last year
News Briefing

CSL and uniQure un­veil three-year da­ta for one-time he­mo­phil­ia B gene ther­a­py that costs $3.5M

Last year
R&D
Pharma

Take­da se­lects for­mer CRISPR Ther­a­peu­tics CMO to lead on­col­o­gy unit; Emile Nuwaysir out at En­so­ma

Last year
People
Peer Review

Syn­log­ic reach­es end of the road for syn­thet­ic bi­ol­o­gy quest af­ter piv­otal da­ta dis­ap­point

Last year
People
R&D

Pre­clin­i­cal biotech Metageno­mi prices $94M IPO at low end of pro­posed range

Last year
Financing
Startups

Sen­ate grills phar­ma CEOs, who emerge from hear­ing on drug prices large­ly un­scathed

Last year
Pharma

Kyver­na surges af­ter IPO, and CEO lays out plans for cell ther­a­py in im­mune dis­eases

Last year
Cell/Gene Tx

House pass­es ban on use of QALYs in fed­er­al health pro­grams

Last year
Pharma
FDA+

Ogilvy Health taps long­time WPP ex­ec Re­na­ta Ma­ia as chief cre­ative of­fi­cer

Last year
People
Pharma

As­traZeneca on 'in­de­pen­den­t' man­u­fac­tur­ing; Sam­sung Bio's next ADC deal

Last year
Manufacturing

Madri­gal re­ports new safe­ty da­ta for NASH can­di­date resme­tirom weeks ahead of PDU­FA date

Last year
R&D

Wall Street: GLP-1 com­peti­tors’ pain is Eli Lil­ly’s gain

Last year
Pharma

Lil­ly picks a Foghorn tar­get; Min­eralys’ $120M PIPE; Sana's $165M of­fer­ing

Last year
News Briefing

As­traZeneca CEO calls open­ing IRA drug price of­fer 'rel­a­tive­ly en­cour­ag­ing' in first char­ac­ter­i­za­tion of talks

Last year
Pharma
FDA+

Neu­rona rais­es $120M to take epilep­sy cell ther­a­py to late-stage de­vel­op­ment

Last year
Financing
Startups

Up­dat­ed: ‘Ruth­less’ pipeline pri­or­i­ti­za­tion, obe­si­ty and Chi­na: Three take­aways from As­traZeneca’s Q4 

Last year
China
Pharma

Catal­ent’s In­di­ana site clos­es out three Form 483s in past two years

Last year
FDA+
Manufacturing

BioN­Tech, Au­to­lus strike wide-rang­ing li­cens­ing and man­u­fac­tur­ing deal for CAR-T ther­a­pies

Last year
Deals
Cell/Gene Tx
First page Previous page 203204205206207208209 Next page Last page
A service from the Financial Times